Neurocrine officer plans sale of 2,154 shares
NEUROCRINE BIOSCIENCES, INC.
Rhea-AI Filing Summary
NEUROCRINE BIOSCIENCES, INC. (NBIX) received a Rule 144 notice that officer Eric Benevich plans to sell up to 2,154 shares of common stock. The shares are expected to be sold on or about September 9, 2026 on NASDAQ through Morgan Stanley Smith Barney LLC after a cash exercise of stock options.
Positive
- None.
Negative
- None.
Key Figures
Shares to be sold under Rule 144: 2,154 shares
Expected sale date: September 9, 2026
Form type: Rule 144 notice of proposed sale
3 metrics
Shares to be sold under Rule 144
2,154 shares
Planned sale of Neurocrine Biosciences, Inc. common stock by an officer
Expected sale date
September 9, 2026
Planned disposition date for the 2,154 shares
Form type
Rule 144 notice of proposed sale
Notice filed for planned sale of restricted/controlled securities
Key Terms
Rule 144, Exercise of Stock Options, Executive Financial Services
3 terms
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Exercise of Stock Options financial
"Common | 09/09/2026 | Exercise of Stock Options | Issuer"
Executive Financial Services financial
"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"
FAQ
What does the Rule 144 filing disclose for NBIX?
It discloses that officer Eric Benevich intends to sell up to 2,154 shares of Neurocrine Biosciences, Inc. common stock under Rule 144, with sales expected around September 9, 2026 after a cash exercise of stock options.
Which broker is named for the NBIX Rule 144 sale?
The planned sale of 2,154 shares of Neurocrine Biosciences, Inc. common stock is to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services, with trading on NASDAQ as stated in the notice.
AI-generated analysis. How Rhea-AI works. Not financial advice.